pyrroles has been researched along with Hand-Foot Syndrome in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 30 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, W; Chen, YH; Dong, BJ; Huang, JW; Huang, YR; Kong, W; Li, MY; Xue, W; Yuan, YC; Zhang, J; Zhou, LX | 1 |
| Fuss, H; Jung, S; Lademann, J | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Adriaansz, S; Beijnen, JH; Blank, CU; Haanen, JB; Huitema, AD; Lankheet, NA; Mallo, H; Schellens, JH | 1 |
| Casado Herráez, A; Currás Freixes, M; Díaz Pérez, JÁ; Ochagavía Cámara, S | 1 |
| Chan, A; Chau, NM; Chong, XJ; Chue, XP; Ho, HK; Kanesvaran, R; Tan, MH; Teo, YL; Wee, HL | 1 |
| Hashimoto, Y; Iizuka, J; Ikezawa, E; Kobayashi, H; Kondo, T; Nozaki, T; Omae, K; Takagi, T; Tanabe, K; Yoshida, K | 1 |
| Dreicer, R; Elson, P; Garcia, JA; Mittal, K; Najjar, YG; Rini, BI; Wood, L | 1 |
| Cserháti, A; Kahán, Z; Maráz, A; Szilágyi, E; Uhercsák, G; Varga, Z | 1 |
| Faivre, S; Grande, E; Hubner, RA; Raymond, E; Valle, JW | 1 |
| Arrowood, CA; Honeycutt, W; Howard, L; Hurwitz, HI; Latta, K; Meadows, KL; Niedzwiecki, D; Rushing, C | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Iguchi, T; Kato, M; Nakatani, T; Ninomiya, N; Tamada, S; Yamasaki, T | 1 |
| Houzawa, H; Komatsu, Y; Nishida, T; Ohki, E; Togo, K; Toyoshima, Y; Ueda, E; Ueno, N; Yoshida, A | 1 |
| Beaumont, JL; Cella, D; Diaz, J; Khan, S; Lai, JS | 1 |
| Bjarnason, GA; Cohen, DP; Davis, MP; Donskov, F; Goldstein, D; Lin, X; Michaelson, MD; Motzer, RJ; Puzanov, I; Rini, BI; Wiltshire, R | 1 |
| Albiges, L; Choueiri, TK; De Velasco, G; Fay, AP; Heng, DY; Kaymakcalan, MD; Kollmannsberger, CK; Kroeger, N; Lee, JL; McKay, RR; North, SA; Rha, SY; Smoragiewicz, M; Wells, JC; Xie, W | 1 |
| Barett, C; Bikas, A; Burman, KD; Clark, BG; Desale, S; Gandhi, R; Jelinek, JS; Kundra, P; Mete, M; O'Keefe, K; Wartofsky, L; Wexler, JA; Wray, L | 1 |
| Aziz, SA; Bhat, GM; Changal, KH; Lone, AR; Mir, MH | 1 |
| Falkowski, S; Jagodzińska-Mucha, P; Klimczak, A; Koseła-Paterczyk, H; Kozak, K; Rogala, P; Rutkowski, P; Świtaj, T; Wągrodzki, M; Ługowska, I | 1 |
| Antón-Aparicio, LM; Cassinello, J; Castellano, D; Esteban, E; González-Larriba, JL; Grande, E; Sepúlveda, J | 1 |
| Adriaansz, S; Beijnen, JH; Blank, CU; Huitema, AD; Lankheet, NA; Mallo, H; Rosing, H; Schellens, JH | 1 |
| Ohtsuka, T | 1 |
| Colecchia, M; Iacovelli, R; Mariani, L; Procopio, G; Torelli, T; Verzoni, E | 1 |
| Bos, WE; de Jonge, MJ; Hamberg, AP; Nijsten, TE | 1 |
| He, H; Shen, Z; Wang, H; Wang, X; Wu, Y; Zhang, C; Zhao, J; Zhou, W; Zhu, Y | 1 |
| Baba, S; Fujita, T; Ishii, D; Iwamura, M; Matsumoto, K; Tabata, K; Yoshida, K | 1 |
| Abrahamova, J; Bortlicek, Z; Buchler, T; Dusek, L; Melichar, B; Pavlik, T; Poprach, A; Puzanov, I; Vyzula, R | 1 |
| Hensley, JR; Kulik, L; Lacouture, ME; Mulcahy, M; Nardone, B; Rademaker, A; West, DP | 1 |
| Chen, CS; Chen, WM; Cheng, CL; Chiu, KY; Ho, HC; Li, JR; Ou, YC; Su, CK; Wang, SS; Yang, CK; Yang, CR | 1 |
1 review(s) available for pyrroles and Hand-Foot Syndrome
| Article | Year |
|---|---|
Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Eruptions; Hand-Foot Syndrome; Humans; Indoles; Mucositis; Pyrroles; Sunitinib | 2015 |
10 trial(s) available for pyrroles and Hand-Foot Syndrome
| Article | Year |
|---|---|
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome.
Topics: Aged; Antineoplastic Agents; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Pyrroles; Seasons; Sunitinib; Sweat | 2013 |
Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Double-Blind Method; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Pilot Projects; Piperazines; Placebos; Protein Kinase Inhibitors; Purines; Pyrroles; Sildenafil Citrate; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hand-Foot Syndrome; Humans; Incidence; Indoles; Japan; Male; Middle Aged; Neutropenia; Prognosis; Proportional Hazards Models; Pyrroles; Severity of Illness Index; Sunitinib; Thrombocytopenia; Treatment Outcome | 2015 |
Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Indazoles; Indoles; Kidney Neoplasms; Lymph Nodes; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Pyrimidines; Pyrroles; Quality of Life; Risk Assessment; Sulfonamides; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2016 |
Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Papillary; Chemotherapy, Adjuvant; Diarrhea; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Indoles; Iodine Radioisotopes; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Pyrroles; Radiotherapy; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |
Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Castration; Diarrhea; Drug Resistance, Neoplasm; Fatigue; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2011 |
Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Diarrhea; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Severity of Illness Index; Sorafenib; Sunitinib | 2012 |
Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Axitinib; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hand-Foot Syndrome; Heparin; Humans; Imidazoles; Indazoles; Indoles; Male; Middle Aged; Niacinamide; Ointments; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyrroles; Severity of Illness Index; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
19 other study(ies) available for pyrroles and Hand-Foot Syndrome
| Article | Year |
|---|---|
[Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Disease-Free Survival; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Multivariate Analysis; Neutropenia; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Thrombocytopenia; Treatment Outcome | 2018 |
Influence of Sorafenib, Sunitinib and Capecitabine on the Antioxidant Status of the Skin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antioxidants; Capecitabine; Carotenoids; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Skin; Sorafenib; Sunitinib | 2018 |
Three cases of sporadic medullary thyroid carcinoma in progression treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Medullary; Combined Modality Therapy; Hand-Foot Syndrome; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neck Dissection; Neoplasms, Second Primary; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Thrombocytopenia; Thyroid Neoplasms; Thyroidectomy | 2014 |
Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cohort Studies; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Quality of Life; Skin; Sunitinib | 2014 |
Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2014 |
A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2014 |
[Therapeutic significance of sunitinib-induced "off-target" side effects].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Hypertension; Hypothyroidism; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Predictive Value of Tests; Pyrroles; Retrospective Studies; Stomatitis; Sunitinib; Treatment Outcome | 2014 |
Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Drug Administration Schedule; Fatigue; Hand-Foot Syndrome; Humans; Indoles; Neuroendocrine Tumors; Neutropenia; Pancreatic Neoplasms; Pyrroles; Stomatitis; Sunitinib; Thyroid Diseases | 2014 |
Prolonging survival in metastatic renal cell carcinoma patients treated with targeted anticancer agents: a single-center experience of treatment strategy modifications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Life Style; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Pyrroles; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2015 |
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Neutropenia; Pyrroles; Sunitinib; Survival Rate; Young Adult | 2015 |
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcin
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Diarrhea; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Mucositis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Renal Cell; Developing Countries; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Mucositis; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Prospective Studies; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sirolimus; Sorafenib; Sunitinib; Survival Rate; White People; Young Adult | 2016 |
Long-term results of therapy with sunitinib in metastatic alveolar soft part sarcoma.
Topics: Adult; Aged; Bone Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sarcoma, Alveolar Soft Part; Sunitinib | 2017 |
Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Biotransformation; Calibration; Carcinoma, Renal Cell; Chromatography, High Pressure Liquid; Dealkylation; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Limit of Detection; Protein Kinase Inhibitors; Pyrroles; Reproducibility of Results; Sunitinib; Sweat; Tandem Mass Spectrometry | 2011 |
Sunitinib-induced hand-foot syndrome in a renal cell carcinoma: a sclerodermatous and rheumatoid arthritis-like case.
Topics: Aged; Antineoplastic Agents; Arthritis, Rheumatoid; Carcinoma, Renal Cell; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Pyrroles; Scleroderma, Diffuse; Sunitinib | 2012 |
Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib | 2012 |
Topical psoralen plus UV-A therapy for tyrosine kinase inhibitor-induced hand-foot syndrome.
Topics: Benzamides; Female; Hand-Foot Syndrome; Humans; Imatinib Mesylate; Indoles; Male; Piperazines; Protein Kinase Inhibitors; PUVA Therapy; Pyrimidines; Pyrroles; Sunitinib | 2012 |
C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Leukopenia; Logistic Models; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Retrospective Studies; Sunitinib; Taste Disorders | 2012 |
Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Exanthema; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Registries; Retrospective Studies; Skin; Sorafenib; Sunitinib; Treatment Outcome | 2012 |